LONDON & CHICAGO--()--Anova Enterprises, Inc. (Anova), a leading technology-enabled contract research organization (CRO) dedicated to accelerating clinical development, proudly announces the appointment of Fred Ma, MD, PhD, Adam Callahan, MBA, and Rhonda Rosen, MBA, CPA., to key executive roles. The expansion of Anova’s leadership team reflects the companies significant growth, and adds decades of transformative leadership in the pharmaceutical, biotechnology, and medical device industries, to Anova's leadership team. The expanded Executive leadership team remains committed to transforming the delivery of complex clinical trials from one where sites are activated in the hope they can identify/enroll patients to one where the right trial is available to patients where they receive care.

Joining the team are:

  • Fred Ma, MD, PhD: appointed as Chief Medical Officer, brings 30 years of global experience in regulatory success, groundbreaking clinical innovation, and executive leadership. He has held leadership positions at Johnson and Johnson, Merck, Innovacyn, RMS Medical, and Cognivue. An expert in oncology, neuroscience, immunology, and cell and gene therapies, Dr. Ma has been instrumental in advancing over 1,000 clinical trials and securing numerous regulatory approvals and product commercializations worldwide. In addition to his contributions to research and development, Dr. Ma has driven exceptional return on investment (ROI) through his leadership in marketing, sales, and operations, not only in the U.S. but also across Europe, South America, and the Asia-Pacific region. Dr. Ma earned his BS/MD from Beijing Capital Medical University, a Doctor of Medical Sciences degree from the University of Tokyo, and completed Ph.D. training at Rutgers University.
  • Adam Callahan, MBA: appointed as VP, Clinical Development, brings over 20 years of leadership experience in clinical development and operations within the pharmaceutical, diagnostics, and medical device industries. He has executive leadership experience at global CROs like Syneos, IQVIA and Agilent Technologies. His expertise in managing molecule-to-market strategies, regulatory compliance, cross-functional and high-performing global teams, and a proven track record of designing and executing clinical trials, fostering collaborative environments, revenue growth, strategic vision and innovative solutions adds exceptional program leadership capabilities to the Anova team.
  • Rhonda Rosen, MBA, CPA: appointed as Chief Finance Officer, brings 30 years senior finance executive leadership experience that spans all areas of finance, banking and administration. She has executive experience in contract research organization (CRO) and life-science companies, including board and investor communications, M&A, public and private financing transactions, and initial public offerings. Her has a proven track record leading the growth and dramatic improvement of multiple early stage, mid-sized and PE/ VC backed companies, including closing over 60 M&A transactions.

Christopher Beardmore, Chief Executive Officer of Anova, said: “We are excited to grow the leadership team at Anova to support our complex clinical trial portfolio. Their unparalleled expertise in clinical development, coupled with their proven track record of global leadership, aligns perfectly with our mission to accelerate clinical development and bring innovative treatments to patients in need. Their vision and experience will play a pivotal role in shaping Anova’s future and advancing our global partnerships.”

Dr. Fred Ma expressed his enthusiasm, added: “I am deeply honored to join Anova during this exciting time. The company’s unwavering commitment to advancing medical innovation and addressing unmet medical needs resonates deeply with my passion and expertise. I look forward to contributing to Anova’s success and delivering transformative healthcare solutions to patients globally.”

Martin Walsh, President of Anova, said: “We are delighted to welcome these exceptional leaders to our team. We have successfully managed compassionate use programs and complex clinical trials for patients with brain, lung, and bladder cancers, COVID and ALS with our AnovaOSTM platform. The team is ideally suited to transform traditional study access into Anova’s vision where the right trial is made available to the right patients where they receive care.”

About Anova

Anova Enterprises, Inc. is a technology-enabled concierge research organization committed to accelerating clinical development for start-up biopharmaceutical companies. By leveraging its proprietary technology platform, AnovaOS™, Anova provides comprehensive solutions for streamlining clinical trials and delivering high-quality results. Focused on innovation and efficiency, Anova is transforming the landscape of clinical research globally.

For more information, please visit www.anovaevidence.com.